Telehealth Firm Disrupts GLP-1 Market with Flat-Rate Pricing

WICHITA FALLS, TX – January 22, 2026 – In a move poised to shake up the lucrative market for weight loss medications, telehealth pharmacy CoreAge Rx has introduced a flat-rate pricing model for compounded GLP-1 drugs, directly targeting patient frustrations over unpredictable costs and insurance hurdles.

The company announced today that it will offer compounded semaglutide, the active ingredient in Ozempic and Wegovy, starting at an equivalent of $99 per month. Compounded tirzepatide, the active ingredient in Mounjaro and Zepbound, will be available starting at $149 per month. The pricing is based on an annual payment plan that includes all dosage levels, physician consultations, and overnight shipping, a stark contrast to the variable, and often exorbitant, costs that have defined the patient experience with these popular drugs.

This all-inclusive approach aims to eliminate the hidden fees and surprise price hikes that patients often encounter as their dosage increases. "Many patients are frustrated by hidden fees, membership charges, and prices that change as their treatment progresses," said Ella Jones, a spokesperson for CoreAge Rx, in a press release. "Our transparent pricing model means patients know exactly what they'll pay from the start. Whether you're taking 2.5mg or 15mg of tirzepatide, the annual cost remains the same. No surprises."

A New Model for a High-Demand Market

The introduction of GLP-1 receptor agonists has been hailed as a breakthrough in obesity treatment, with clinical studies showing users can achieve significant weight loss, often between 15% and 22% of their body weight. This effectiveness has fueled unprecedented demand, but access remains a significant challenge. Without robust insurance coverage, which many plans lack for weight loss indications, brand-name medications can cost upwards of $1,000 per month, placing them far out of reach for the average consumer.

CoreAge Rx's model circumvents this barrier by operating on a direct-to-consumer, cash-pay basis. By bundling the medication—sourced from compounding pharmacies—with the required medical oversight and logistics into a single, predictable annual fee, the company is betting it can attract a large segment of the market priced out of traditional channels. The promise is simple: one payment for a year's worth of treatment, with no dosage-based price increases. This is particularly significant as GLP-1 treatments require a titration period, where patients start on a low dose that is gradually increased over several months to the effective maintenance level.

Under conventional pricing, each dosage increase can come with a higher price tag. The flat-rate structure removes this financial penalty for progressing through the clinically recommended treatment protocol, a major pain point for patients attempting to budget for their long-term care.

The Compounding Conundrum: Access vs. Regulation

Central to CoreAge Rx's ability to offer lower prices is its reliance on compounded medications. The company states it partners exclusively with 503A state board-regulated compounding pharmacies. These pharmacies are permitted to create customized medications for individual patients based on a specific prescription. This practice is distinct from mass manufacturing and is legal under federal law, particularly when the brand-name version of a drug is listed on the FDA's drug shortages list, as has frequently been the case for semaglutide and tirzepatide.

However, the use of compounded GLP-1s exists in a gray area that warrants consumer caution. The U.S. Food and Drug Administration (FDA) has issued public warnings about the potential risks of using compounded versions of these drugs. The agency has stated that compounded drugs are not FDA-approved and do not undergo the same rigorous pre-market review for safety, efficacy, and quality as commercially manufactured pharmaceuticals. The FDA has also received adverse event reports related to compounded semaglutide and has expressed concern that some compounders may be using different salt forms of the active ingredients, whose safety and effectiveness have not been evaluated.

While CoreAge Rx emphasizes its partnership with state-regulated 503A facilities—which are subject to state board of pharmacy oversight—this level of regulation is different from the stringent standards applied to FDA-approved drug manufacturers. This creates a critical trade-off for patients: the potential for greatly enhanced affordability and access versus the unevaluated risks associated with drugs that have not passed through the FDA's gold-standard approval process.

Navigating the Telehealth Pathway to Weight Loss

For consumers, the process offered by CoreAge Rx reflects the streamlined nature of modern telehealth. Prospective patients complete a brief online health assessment, which is then reviewed by a U.S.-licensed, board-certified physician. This review determines if a GLP-1 medication is appropriate and safe for the patient. In some states, telehealth regulations may require a live video or phone consultation to establish a doctor-patient relationship before a prescription can be issued.

Once approved, the prescription is sent to a partner compounding pharmacy, and the medication is shipped overnight in cold packaging directly to the patient's home, typically within three to five business days. The model includes ongoing support and monthly check-ins to monitor progress, manage side effects, and adjust dosages under physician guidance. This digital-first approach eliminates the need for repeated in-person doctor visits, adding a layer of convenience to the treatment process.

Patients considering this route should be aware of the terms. While a full refund is issued if a physician does not approve treatment, the initial consultation fee is generally non-refundable. Furthermore, due to state and federal laws, all sales are final once the medication has been shipped. This direct-to-patient model places a significant emphasis on consumer due diligence in evaluating the provider and understanding the nature of compounded medications before committing to an annual plan.

Reshaping the Competitive Landscape

CoreAge Rx is not the only player in the telehealth weight loss space, but its aggressive, transparent pricing strategy sets it apart from many competitors. Other platforms like Calibrate, Found, and WeightWatchers Clinic also offer access to GLP-1s, but often with different models that may involve monthly membership fees, separate medication costs dependent on insurance, and programs that bundle medication with intensive coaching.

By offering a clear, all-inclusive annual price for compounded alternatives, CoreAge Rx is placing direct pressure on the entire market. This could force competitors to simplify their own pricing and may accelerate the trend of patients opting for cash-pay telehealth services over navigating complex insurance bureaucracies. The success of this model may also heighten consumer expectations for price transparency across other areas of healthcare.

As more companies enter this space, the market for GLP-1s is rapidly bifurcating between the high-cost, FDA-approved brand-name drugs and the more affordable but less-regulated compounded alternatives. While this expands options for patients, it also increases the need for both regulatory oversight and patient education to ensure that the pursuit of affordable weight management does not come at the expense of safety.